Astra Zeneca suffers slight setback...

AstraZeneca (AZN). The Anglo-Swedish drugmaker’s drive to extend the life of its blockbuster acid reflux drug Nexium through new uses was set back on Tuesday after U.S. regulators delayed approval of a drug combining it with aspirin. Nexium faces the loss of patent protection in key markets and the company is developing novel formulations to extend its franchise.